A Randomized Trial of NSAID Dosing Strategies Read more about A Randomized Trial of NSAID Dosing Strategies
Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus Read more about Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008) Read more about Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy Read more about A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Read more about Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Read more about Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
COVID-19 Vaccine Response in Sickle Cell Disease Read more about COVID-19 Vaccine Response in Sickle Cell Disease
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH Read more about A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH Read more about A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH